KEESHA STEWART: Open Payments
NPI 1235895269 · CHESAPEAKE, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,744 in 89 payments from 17 companies in 2025. Trend: 2023 $2,692 · 2024 $2,154 · 2025 $1,744
Food & beverage: $1,740Education: $4
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 16 | $314 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $246 |
| Neurocrine BioSciences, Inc. | 9 | $190 |
| Otsuka America Pharmaceutical, Inc. | 9 | $178 |
| ABBVIE INC. | 9 | $152 |
| Axsome Therapeutics, Inc. | 8 | $137 |
| Vanda Pharmaceuticals Inc. | 4 | $109 |
| Supernus Pharmaceuticals, Inc. | 4 | $77 |
| Janssen Pharmaceuticals, Inc | 3 | $72 |
| Teva Pharmaceuticals USA, Inc. | 4 | $66 |
Products named: ARISTADA, CAPLYTA, INGREZZA, REXULTI, VRAYLAR, Auvelity, FANAPT, Qelbree.
Industry payments across VA — which companies pay providers there.
